B O Williams, H Hull, P McSorley, M F Frosolono, R L Sanders
Index: Ann. Allergy Asthma Immunol. 76(5) , 432-8, (1996)
Full Text: HTML
Acrivastine is a second-generation H1-antagonist chemically related to triprolidine, but more polar and with less central nervous system penetration than triprolidine.The efficacy of the antihistamine-decongestant combination product (Semprex-D capsules) containing acrivastine 8 mg plus pseudoephedrine HCl 60 mg was evaluated for the treatment of seasonal allergic rhinitis symptoms.A total of 676 patients sensitive to mountain cedar pollen was enrolled into a 6-center, randomized, double-blind, placebo-controlled, parallel, 4-group study designed to compare acrivastine + pseudoephedrine, acrivastine, pseudoephedrine, and placebo. Patients with demonstrable diary symptom scores at baseline took study medication (4 doses/day) and recorded symptom scores twice daily for 2 weeks. The effectiveness of the acrivastine + pseudoephedrine combination was examined relative to the individual components and placebo in terms of changes in diary symptom scores.Over the 2-week period, the combination of acrivastine plus pseudoephedrine was significantly more effective than (1) acrivastine, pseudoephedrine, and placebo (P < .001) for relief of all symptoms; (2) pseudoephedrine (P < .001) for relieving allergy symptoms, ie, running nose, sneezing, itchy nose/throat and tearing; and (3) acrivastine (P < .001) for reducing nasal congestion. Relative to placebo, small increases in adverse experience rates were observed with acrivastine + pseudoephedrine for dry mouth, insomnia, somnolence, and headache.These findings in a large clinical trial demonstrate (1) the efficacy of acrivastine and (2) that each component of the combination of acrivastine 8 mg plus pseudoephedrine HCl 60 mg contributes to the overall efficacy, thereby supporting the conclusion that the combination is rational, safe, and effective for the treatment of allergic rhinitis.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Acrivastine
CAS:87848-99-5 |
C22H24N2O2 |
Identification of novel functional inhibitors of acid sphing...
2011-01-01 [PLoS ONE 6 , e23852, (2011)] |
Simultaneous analysis of the H1-antihistamine acrivastine an...
2005-04-01 [J. Pharm. Biomed. Anal. 37(4) , 663-7, (2005)] |
Onset-of-action for antihistamine and decongestant combinati...
2000-04-01 [Ann. Allergy Asthma Immunol. 84(4) , 451-9, (2000)] |
Quantification of antihistamine acrivastine in plasma by sol...
2007-01-04 [J. Pharm. Biomed. Anal. 43(1) , 293-7, (2007)] |
Evaluation and comparison of five matrix excipients for the ...
2004-01-01 [Drug Dev. Ind. Pharm. 30(10) , 1009-17, (2004)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved